Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 363 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: LDL Clear all
Completed Phase 3 Interventional Results available

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

NCT01879319
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab AMD, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
22
States / cities
Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

NCT03531905
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
Interventions
Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet, Placebo oral capsule
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Nov 7, 2026, 5:42 AM EST
Not listed Not applicable Interventional

Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease

NCT01427218
View directory record Official record
Conditions
Coronary Heart Disease, Myocardial Infarction
Interventions
Titration of medications, Lifestyle Counseling, Medication Counseling, Usual Care with Medication Reconciliation
Other · Behavioral
Lead sponsor
Middle Tennessee Research Institute
Other
Eligibility
60 Years to 90 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Nov 7, 2026, 5:42 AM EST
Recruiting Not applicable Interventional

A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients

NCT06571162
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Clinical Pharmacy Team, Usual Care
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Nov 7, 2026, 5:42 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

FTIH of ECC4703 in Healthy Volunteers

NCT05552274
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
ECC4703, Placebo
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 7, 2026, 5:42 AM EST
Terminated No phase listed Observational

Dried Blood Spot- Statin Pilot Study

NCT02402803
View directory record Official record
Conditions
Hyperlipidemias, Cardiovascular Diseases
Interventions
Dried blood spot testing and phlebotomy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Nov 7, 2026, 5:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Protein Sources and Atherogenic Dyslipidemia

NCT01427855
View directory record Official record
Conditions
Cardiovascular Disease, Dyslipidemia, Insulin Resistance, Inflammation
Interventions
High saturated fat red meat diet, High saturated fat non-meat diet, High saturated fat white meat diet, Low saturated fat red meat diet, Low saturated fat white meat diet, Low saturated fat non meat diet
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
30 Years to 65 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Nov 7, 2026, 5:42 AM EST
Not yet recruiting Not applicable Interventional

Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)

NCT07355894
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
Interventions
AI-Detected CAC Notification and Care Facilitation
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 74 Years
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Pleasanton, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Completed Not applicable Interventional

Comparison of Outreach Approaches to Increase Enrollment in a Healthy Cholesterol Study

NCT02086539
View directory record Official record
Conditions
Diabetes
Interventions
Large Envelope, Priority Mail, Amazon
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

NCT02072161
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Statin Therapy
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
40
States / cities
Muscle Shoals, Alabama • Chandler, Arizona • Chino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Nov 7, 2026, 5:42 AM EST
Completed No phase listed Observational

Using Nudges to Implement Comparative Effectiveness

NCT01575171
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Nudge
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

NCT06692764
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Placebo, AZD0780
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
26
States / cities
Inglewood, California • Northridge, California • Pomona, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Recruiting Phase 4 Interventional

DESIFOR-EXPAND (MHIF)

NCT06804980
View directory record Official record
Conditions
Statin Therapy, Statin Adverse Reaction, Statin
Interventions
Rosuvastatin (Crestor), Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Nov 7, 2026, 5:42 AM EST
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Not yet recruiting Not applicable Interventional

Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3

NCT07919353
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Cascade Screening
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 3 Interventional

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

NCT00459745
View directory record Official record
Conditions
Combined Hyperlipidemia
Interventions
Pravafen, Pravastatin, Fenofibrate
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
57
States / cities
Phoenix, Arizona • Sierra Vista, Arizona • Long Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Nov 7, 2026, 5:42 AM EST
Not listed No phase listed Observational

Impact of a Chewable Plant Sterol Supplement on LDL-C in A Real-World Setting

NCT04642742
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Chewable plant sterol
Dietary Supplement
Lead sponsor
Piper Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Nov 7, 2026, 5:42 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

NCT07626281
View directory record Official record
Conditions
Inclisiran Formulation
Interventions
Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
6
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 7, 2026, 5:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans

NCT01858376
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Capros dietary supplement
Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
21 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Nov 7, 2026, 5:42 AM EST
Completed Phase 2 Interventional

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

NCT03549260
View directory record Official record
Conditions
LDL Cholesterol
Interventions
LIB003
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Nov 7, 2026, 5:42 AM EST
Completed Not applicable Interventional

Improving Adherence to Pharmacological Treatment

NCT00848224
View directory record Official record
Conditions
Medication Adherence
Interventions
systems-based and pharmacist-mediated program
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
30 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Nov 7, 2026, 5:42 AM EST
Recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

NCT07619118
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3, laroprovstat/rosuvastatin 4, Placebo to match laroprovstat/rosuvastatin 1,2,3, Placebo to match laroprovstat/rosuvastatin 4, Rosuvastatin 1, Rosuvastatin 2, Rosuvastatin 3, Rosuvastatin 4, Placebo to match Rosuvastatin
Combination Product · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Sun City West, Arizona • Gardena, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 7, 2026, 5:42 AM EST